← Back to Home

Reading Signals Around Tumors Through a Blood Draw: Plasma RNA May Help Predict CAR-T Outcomes in Lymphoma

A study of 91 patients found that a set of RNA features in plasma before treatment was associated with disease control after CAR-T therapy. This window into the tumor microenvironment still needs larger-scale validation before it can become a clinical decision-making tool.

By SURL BioNews

For patients with lymphoma preparing to receive CAR-T cell therapy, whether treatment will bring lasting remission often takes time to become clear. A team from Cornell University and Dana-Farber Cancer Institute has now found that blood drawn before treatment may already hold some clues: cell-free RNA in plasma can reflect the cellular environment surrounding tumors, and these signals are associated with subsequent treatment outcomes.

According to a Cornell University report on November 18 about a study published the same day in *Cell Reports Medicine*, the team analyzed pretreatment plasma from 91 patients with large B-cell lymphoma. The patients belonged to three cohorts, all of which received axicabtagene ciloleucel (Yescarta). Those with higher scores for a particular RNA signature had an approximately 80% lower risk of disease progression than those with lower scores. This is a difference in risk between groups and cannot be interpreted as an individual patient having an 80% chance of being cured.

This signature points to a “lymph node-like” tumor microenvironment. Tumors do not grow in isolation; surrounding immune cells, supporting tissue, and vascular cells jointly influence treatment response. The researchers sought to use cell-free RNA released by cells into the blood to read some of the information that previously required a tissue biopsy. These signals in plasma were also stronger in patients who responded to treatment.

A key comparison came from paired peripheral blood mononuclear cells: the researchers did not see the same signals in these circulating cells. This supports the possibility that plasma RNA carries information originating from tissue, rather than merely reflecting changes in immune cells in the blood. However, this finding is still insufficient to establish the origin of each RNA fragment or prove that the microenvironment itself caused the differences in treatment outcomes.

An early version of the same study was made public as a preprint on March 18. Its PubMed record explicitly labels it as not yet peer reviewed, and it should be distinguished from the November journal publication. The preprint also disclosed that some authors were involved in patent applications related to cell-free nucleic acids and that Conor Loy and Iwijn De Vlaminck held equity in Romix Biosciences. These interests are necessary context when assessing subsequent test development.

Background

Progress in CAR-T involves both changing how the cells are manufactured, including attempts to generate CAR-T cells directly inside patients, and understanding why the same therapy produces widely differing results across patients. This plasma RNA study focuses on the latter, aiming to characterize patients’ tumor environments more clearly before treatment begins and provide a basis for risk stratification and combination therapy research.

For now, this remains a study of a biomarker associated with treatment outcomes. Having three cohorts does not mean that validation across institutions has been completed, and the findings cannot be directly generalized to all CAR-T products or other cancers. The team said the next step requires larger, multi-institutional studies. Even if the test can reliably predict risk, researchers must still demonstrate that adjusting treatment based on its results actually improves patient outcomes before it can enter routine clinical practice.

References

  1. Cornell Chronicle
  2. PubMed / medRxiv